AB Science unveils advances in the treatment of acute myeloid leukemia

AB Science has published promising Phase 1 results for its combination treatment of AB8939 and venetoclax for relapsed or refractory acute myeloid leukemia (AML). The results demonstrate high tolerability and a 100% partial response rate after the first cycle of treatment. This combination effectively targets cancer cells and stem cells, reducing the risk of relapse.

Nicholas J. Short of MD Anderson Cancer Center highlights the significant potential of AB8939 for high-risk AML subtypes. With a market estimated at over €2 billion for refractory treatments, AB Science is considering an extension study to confirm these encouraging preliminary data.